Hormonal
Growth hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) supplementation improves cardiovascular health by attenuating mitochondrial oxidative stress, upregulating antioxidant enzymes, and preserving endothelial progenitor cell function.
Maintaining healthy levels of Growth Hormone and IGF-1 is critical for heart health in aging. Deficiency in these hormones is linked to premature atherosclerosis and higher cardiovascular mortality. While extremely high levels may have other risks, low-normal levels are associated with increased heart disease risk, suggesting that preserving this hormonal axis is beneficial for vascular longevity.
IGF-1, via upregulating antioxidant enzymes and exerting mitochondrial protective effects, significantly attenuates mitochondrial oxidative stress in aging, resulting in inhibition of endothelial activation and vascular inflammation. IGF-1 also promotes progenitor cell function, improves NO bioavailability, and limits apoptotic cell death...
Why this rating
Supported by human epidemiological data and rodent models, though human clinical trials for supplementation are noted as needing further study.
Source
Mechanisms of Vascular Aging: New Perspectives
Zoltán Ungvári et al. · The Journals of Gerontology Series A · 2010
DOI 10.1093/gerona/glq113
More from this paper
- Chronic low-grade inflammation (inflammaging) drives vascular aging by promoting oxidative stress, endothelial dysfunction, and atherosclerosis through the upregulation of cytokines like TNF-alpha and NF-kB activation.Strong
- Regular aerobic exercise reverses age-related endothelial progenitor cell (EPC) dysfunction by increasing both the number and migratory activity of EPCs in older adults.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →